EU/3/02/121

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in Septebmer 2017 at the end of the 10-year period of market exclusivity.

On 13 November 2002, orphan designation (EU/3/02/121) was granted by the European Commission to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, for 5-aminolevulinic acid hydrochloride for the intra-operative photodynamic diagnosis of residual glioma.

5-aminolevulinic acid hydrochloride has been authorised in the EU as Gliolan since 7 September 2007.

Key facts

Active substance
5-aminolevulinic acid hydrochloride
Medicine name
Gliolan
Disease / condition
Intra-operative photodynamic diagnosis of residual glioma
Date of decision
14/11/2002
Outcome
Expired
Orphan decision number
EU/3/02/121

Sponsor's contact details

medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D-22880 Wedel
Germany
Tel. + 49 4103 8006 0
Fax + 49 4103 8006 100
E-mail: contact@medac.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating